Literature DB >> 26905038

The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis.

Danielle M Moskow1, Jean Addington2, Carrie E Bearden3, Kristin S Cadenhead4, Barbara A Cornblatt5, Robert Heinssen6, Daniel H Mathalon7, Thomas H McGlashan8, Diana O Perkins9, Larry J Seidman10, Ming T Tsuang11, Tyrone D Cannon12, Scott W Woods13, Elaine F Walker14.   

Abstract

BACKGROUND: Prodromal syndromes often begin in adolescence - a period of neurodevelopmental changes and heightened stress sensitivity. Research has shown elevated stress and cortisol in individuals at clinical high risk (CHR) for psychosis. This cross-sectional study examined relations of age and pubertal status with cortisol and self-reported stress in healthy controls (HCs) and CHR adolescents. It was hypothesized that the relations of age and pubertal stage with cortisol and stress would be more pronounced in CHR youth.
METHODS: Participants were 93 HCs and 348 CHR adolescents from the North American Prodrome Longitudinal Study (NAPLS). At baseline, measures of stress (Daily Stress Inventory - DSI), Tanner stage (TS), and salivary cortisol were obtained.
RESULTS: ANCOVA revealed increased DSI scores with age for both groups, and higher DSI scores in CHR adolescents than HCs, with a more pronounced difference for females. Contrary to prediction, with age controlled, HCs showed greater TS-related DSI increases. Analysis of cortisol showed no significant interactions, but a main effect of age and a trend toward higher cortisol in the CHR group. Correlations of cortisol with TS were higher in HC than CHR group.
CONCLUSIONS: Stress measures increased with age in HC and CHR adolescents, and DSI scores also increased with TS in HCs. The results do not support a more pronounced age or TS increase in stress measures in CHR adolescents, but instead suggest that stress indices tend to be elevated earlier in adolescence in the CHR group. Potential determinants of findings and future directions are discussed.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high risk; Cortisol; Psychosis; Puberty; Schizophrenia; Stress

Mesh:

Substances:

Year:  2016        PMID: 26905038      PMCID: PMC4821739          DOI: 10.1016/j.schres.2016.02.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  46 in total

Review 1.  Prediction and prevention of psychosis in youth at clinical high risk.

Authors:  Jean Addington; Robert Heinssen
Journal:  Annu Rev Clin Psychol       Date:  2011-12-12       Impact factor: 18.561

2.  Age and puberty differences in stress responses during a public speaking task: do adolescents grow more sensitive to social evaluation?

Authors:  S R Sumter; C L Bokhorst; A C Miers; J Van Pelt; P M Westenberg
Journal:  Psychoneuroendocrinology       Date:  2010-06-11       Impact factor: 4.905

Review 3.  The development of psychotic disorders in adolescence: a potential role for hormones.

Authors:  Hanan D Trotman; Carrie W Holtzman; Arthur T Ryan; Daniel I Shapiro; Allison N MacDonald; Sandra M Goulding; Joy L Brasfield; Elaine F Walker
Journal:  Horm Behav       Date:  2013-07       Impact factor: 3.587

Review 4.  Much ado about much: stress, dynamic biomarkers and HPA axis dysregulation along the trajectory to psychosis.

Authors:  Jai L Shah; Ashok K Malla
Journal:  Schizophr Res       Date:  2015-01-22       Impact factor: 4.939

5.  Stress exposure and sensitivity in the clinical high-risk syndrome: initial findings from the North American Prodrome Longitudinal Study (NAPLS).

Authors:  Hanan D Trotman; Carrie W Holtzman; Elaine F Walker; Jean M Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert K Heinssen; Daniel H Mathalon; Ming T Tsuang; Diana O Perkins; Larry J Seidman; Scott W Woods; Thomas H McGlashan
Journal:  Schizophr Res       Date:  2014-11-07       Impact factor: 4.939

6.  Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone.

Authors:  W F Blum; P Englaro; S Hanitsch; A Juul; N T Hertel; J Müller; N E Skakkebaek; M L Heiman; M Birkett; A M Attanasio; W Kiess; W Rascher
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

7.  The onset of puberty: effects on the psychophysiology of defensive and appetitive motivation.

Authors:  Karina M Quevedo; Stephen D Benning; Megan R Gunnar; Ronald E Dahl
Journal:  Dev Psychopathol       Date:  2009

8.  Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.

Authors:  Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante
Journal:  Schizophr Res       Date:  2009-09-13       Impact factor: 4.939

9.  Salivary cortisol and dehydroepiandrosterone in relation to puberty and gender.

Authors:  Clare Netherton; Ian Goodyer; Alison Tamplin; Joe Herbert
Journal:  Psychoneuroendocrinology       Date:  2004-02       Impact factor: 4.905

10.  A self-report measure of pubertal status: Reliability, validity, and initial norms.

Authors:  A C Petersen; L Crockett; M Richards; A Boxer
Journal:  J Youth Adolesc       Date:  1988-04
View more
  2 in total

1.  Cortisol Responses to Naturally Occurring Psychosocial Stressors Across the Psychosis Spectrum: A Systematic Review and Meta-Analysis.

Authors:  Alexis E Cullen; Sushma Rai; Meghna S Vaghani; Valeria Mondelli; Philip McGuire
Journal:  Front Psychiatry       Date:  2020-06-11       Impact factor: 4.157

Review 2.  Inflammation, Stress Response, and Redox Dysregulation Biomarkers: Clinical Outcomes and Pharmacological Implications for Psychosis.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  Front Psychiatry       Date:  2017-10-25       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.